FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a first-of-its-kind blood test for Alzheimer's biomarkers developed through a partnership between Roche and Eli Lilly.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Food and Drug Administration has officially cleared a new blood test designed to aid in the evaluation of Alzheimer's disease. This diagnostic tool was developed through a collaboration between pharmaceutical and diagnostic giants Roche and Eli Lilly. The clearance marks a significant regulatory milestone for the two companies involved in the development process. Coverage of this development has been widespread across business and medical news outlets. Reuters, Forbes, and the Wall Street Journal have all reported on the FDA's approval of the Roche and Eli Lilly test. Meanwhile, Fierce Biotech has specifically highlighted that this is a first-of-its-kind biomarker blood test, emphasizing the novelty of the technology.
WashU Medicine has also provided coverage, noting that the primary function of the test is to assist healthcare providers in the evaluation process for Alzheimer's disease. The consistency across these five sources indicates a high level of industry interest in the rollout of this diagnostic tool. To understand why this development is significant, it is necessary to look at the current landscape of Alzheimer's diagnosis. Traditionally, identifying biomarkers for the disease has often required more invasive or expensive procedures. By moving the evaluation process to a blood test, the FDA-cleared tool developed by Roche and Eli Lilly aims to streamline the diagnostic pathway. This shift toward biomarker-based blood testing represents a change in how the medical community approaches the early detection and evaluation of the disease, potentially altering the standard of care for patients and providers.
Looking forward, the industry will be monitoring the integration of this test into clinical practice. Since the FDA has already granted clearance, the next phase involves the actual deployment of the test by Roche and Eli Lilly. Future coverage is expected to focus on the availability of the test in medical facilities and the specific ways in which it will be used to aid in the evaluation of patients. While the technical approval is complete, the practical application of this first-of-its-kind biomarker test will be the primary point of interest for medical professionals and patients alike.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (94% supported) Updated 83d ago.
Quick answers
Who developed the new Alzheimer's blood test?
The test was developed by Roche and Eli Lilly.
What did the FDA specifically clear this test for?
The FDA cleared the test to aid in the evaluation for Alzheimer's disease using biomarkers.
Why is this test described as 'first-of-its-kind'?
According to Fierce Biotech, it is a first-of-its-kind Alzheimer's biomarker blood test.
Coverage (14)
- Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test MedTech Dive · 83d ago
- FDA approves new Alzheimer’s blood test from Roche, Eli Lilly WTHR · 83d ago
- US FDA clears Roche-Lilly single-biomarker blood test that helps check for Alzheimer’s-linked changes ThePrint · 83d ago
- FDA Approves New Blood Test to Identify Signs of Alzheimer’s Yahoo · 83d ago
- FDA approves new blood test for Alzheimer’s disease The Hill · 83d ago
- Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance CNN · 83d ago
- FDA approves a new blood test to detect signs of Alzheimer’s The Washington Post · 83d ago
- FDA clears Roche and Eli Lilly's Alzheimer's blood test for primary and specialty care qz.com · 83d ago
- Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance Reuters · 84d ago
- FDA Clears Roche And Eli Lilly’s Alzheimer’s Blood Test Forbes · 84d ago
- Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test Fierce Biotech · 84d ago
- FDA clears blood test to aid evaluation for Alzheimer’s disease WashU Medicine · 84d ago
- FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly WSJ · 84d ago
- FDA approves first Alzheimer's blood test for Americans as young as 40 New Atlas · 84d ago
Topics
Related trends
The GLP-1 boom has a dark side
The FDA orders eye risk warnings on GLP-1 medications like Ozempic and Zepbound, prompting expert guidance.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson is reportedly nearing a multibillion-dollar acquisition of eye disease biotech firm Ollin Biosciences.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
The Largest Alzheimer's Genetics Study Yet Found 48 New Links. The Most Promising Clue Isn't About Memory
The largest Alzheimer's genetics study yet has uncovered 48 new links, highlighting how genetics and sleep interact.
Stanford Scientists Discover Resting Brain Activity May Predict Alzheimer's Years Before Memory Decline
Stanford researchers identify resting brain signals that could flag Alzheimer's disease years before memory symptoms emerge, according to coverage from Science Daily, ScienceAlert, and Yahoo.